title: Topiramate, pseudotumor cerebri, weight-loss and glaucoma: an ophthalmologic perspective.
abstract: Approved for the treatment of epilepsy and migraine prophylaxis, topiramate also acts as a carbonic anhydrase inhibitor implying a potential role in the treatment of pseudotumor cerebri (PTC). Topiramate has a propensity to cause anorexia with consequent weight loss, which alone may be curative in PTC. Prescribers must be aware of several reported cases of acute secondary angle-closure glaucoma reported in patients treated with topiramate.
authors.affiliation: Loyola University Medical Center, Maywood, IL 60153, USA.
authors.forename: Patrick L
authors.initials: PL
authors.lastname: Alore
authors.forename: Walter M
authors.initials: WM
authors.lastname: Jay
authors.forename: Mícheál P
authors.initials: MP
authors.lastname: Macken
mesh_terms: D011307:Drug Prescriptions; D005632:Fructose / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005901:Glaucoma / Q000139:chemically induced*; D006801:Humans; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D011559:Pseudotumor Cerebri / Q000188:drug therapy*; D012307:Risk Factors; D000077236:Topiramate; D016896:Treatment Outcome; D015431:Weight Loss / Q000187:drug effects*
chemical_list: D018696:Neuroprotective Agents; D000077236:Topiramate; D005632:Fructose